Cancer Treatment Toxicities: Molecular Insights and Novel Therapeutic Approaches
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 1673
Special Issue Editors
Interests: inflammation; cancer; cancer chemotherapy toxicities
Special Issue Information
Dear Colleagues,
Cancer is a group of challenging diseases with high incidence and mortality. It is one of the leading causes of death in the world. According to the Global Cancer Observatory, 30.2 million new cases of cancer and 16.3 million deaths are expected by 2040. There are also an estimated 50 million current survivors of this pathology, many of whom have sequelae from the toxic effects of oncological treatments. Remarkably, the still-unsatisfactory knowledge of the pathogenesis of most of these side effects is reflected in the small number of protective therapeutic options. Consequently, adverse severe effects often lead to treatment discontinuation, compromising its overall effectiveness, and increasing the costs for the health system, becoming a critical public health problem.
Identifying molecular targets to develop novel therapeutic approaches opens perspectives for the effective clinical management of the side effects of cancer treatment, reducing morbidity and increasing patients’ quality of life.
The journal Pharmaceuticals welcomes high-quality reviews and original articles that focus on experimental, clinical, or translational research on the pathogenesis of cancer treatment toxicities and the discovery of novel therapeutic compounds to manage these side effects. The collection of manuscripts will be published as a Special Issue.
Dr. Roberto César Pereira Lima-Júnior
Dr. Deysi Viviana Tenazoa Wong
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer treatment toxicities
- side effects
- pathogenesis
- inflammation
- pain
- animal models
- drug target discovery
- preclinical and clinical drug research
- natural compounds
